This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

ChinaBio® Partnering Forum

Event begins in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Kerry Hotel Pudong
September 10–11, 2024 | Shanghai, ChinaSeptember 16–17, 2024 | Virtual

Shaan C. Gandhi
VP, and Head of Strategic Partnerships at Pfizer
Speaker

Profile

Shaan C. Gandhi is Vice President and Head of Strategic Partnerships for Pfizer Ignite, an organization that leverages Pfizer’s R&D resources and expertise to accelerate the development of strategic therapies and therapeutic platforms within the broader biotechnology ecosystem. Before Pfizer, Shaan served as Director at Northpond Ventures, where he led the firm's biotechnologies team. Prior to that role he was Principal at the Longwood Fund, where he co-founded and served as President of Pyxis Oncology (NASDAQ: PYXS), an antibody-drug conjugate and monoclonal antibody oncology company. In addition to his role at Pfizer, he also serves on the board of 1910 Genomics, a private biotechnology company building the infrastructure layer for tech-enabled drug discovery.

In his prior investor roles, Shaan served on the boards of Candel Therapeutics (NASDAQ: CADL), DICE Therapeutics (NASDAQ: DICE, acquired by Eli Lilly), Kyverna Therapeutics (NASDAQ: KYTX), Vigil Neuroscience (NASDAQ: VIGL) and on multiple private boards. He started his career as an attending hospitalist at Massachusetts General Hospital, where he also did his residency in internal medicine. He holds an MD from Harvard Medical School; an MBA from Harvard Business School, where he was a Baker Scholar; a DPhil in medical oncology from the University of Oxford, where he was a Rhodes Scholar; and a BS with honors in biochemistry from Case Western Reserve University.

Agenda Sessions

  • Keynote panel: Achieving renewed success in China thorough increased collaboration, enhanced asset valuation and international reach

    09:30